Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a late-stage biopharmaceutical issuer focused on CNS, inflammatory, and cardiometabolic diseases, Reviva uses its filings to report on clinical development, financing activities, governance matters, and listing status for its common stock and warrants on the Nasdaq Capital Market.
Core documents for RVPH include periodic reports and current reports on Form 8-K. Recent 8-K filings describe registered public offerings of common stock and series warrants, the intended use of proceeds for research and development and general corporate purposes, and material agreements such as securities purchase agreements and placement agency agreements. Other 8-Ks address topics like amendments to the company’s bylaws, Nasdaq listing compliance notices, and press releases containing financial results and operating metrics.
Reviva’s definitive proxy statement on Schedule 14A provides detail on board elections, auditor ratification, advisory votes on executive compensation, and capital structure proposals. These include increasing authorized shares of common stock and authorizing the board to implement a reverse stock split within a specified range, which relate to maintaining flexibility for future financings and potential compliance with Nasdaq’s minimum bid price requirement.
Through this page, users can access RVPH filings such as Form 8-K for material events, DEF 14A for proxy matters, and other registered offering documents referenced in the company’s disclosures. Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in capital structure, clinical and regulatory updates mentioned in furnished press releases, and developments affecting Nasdaq listing standards. Investors can also review disclosures about Reviva’s common stock and warrants (RVPH and RVPHW), quorum changes for shareholder meetings, and information incorporated by reference into registration statements.
Reviva Pharmaceuticals Holdings, Inc. disclosed a joint Schedule 13G filing showing a group of filers—Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander—each reporting 793,952 shares, representing 6.2% of the class.
The filing states these shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion. The submission includes a Joint Filing Agreement dated March 27, 2026 and lists the issuer CUSIP 76152G209.
Reviva Pharmaceuticals Holdings, Inc. reported full year 2025 results, highlighting progress toward late-stage development of brilaroxazine for schizophrenia. The FDA recommended a second Phase 3 trial, and Reviva plans to start the RECOVER-2 registrational study in mid-2026 as part of a future NDA package.
For 2025, Reviva posted a net loss of $19.9 million, improving from a $29.9 million net loss in 2024 as total operating expenses fell to $20.2 million from $30.8 million. Research and development expenses declined to $11.7 million, while general and administrative costs rose modestly to $8.5 million.
Cash and cash equivalents were $14.4 million as of December 31, 2025, slightly above the prior year. Stockholders’ equity increased to $8.6 million, supported by higher additional paid-in capital and a larger share count, with 5,872,865 common shares issued and outstanding at year-end.
Reviva Pharmaceuticals Holdings, Inc. files its annual report describing a late-stage CNS and inflammatory disease pipeline led by brilaroxazine for schizophrenia. The company reports positive results from a large Phase 3 RECOVER trial and a 12‑month extension showing durable efficacy and generally favorable safety.
FDA has asked Reviva to run an additional Phase 3 schizophrenia study (RECOVER‑2) using 30 mg and 50 mg doses before submitting a new drug application, with trial activities expected to start in 2026 and completion targeted for 2027. Brilaroxazine also holds orphan drug designations for pulmonary arterial hypertension and idiopathic pulmonary fibrosis and has encouraging preclinical data in both.
To support operations and development, Reviva executed a May 2025 at‑the‑market program and a March 2026 public offering, raising cash through common stock, pre‑funded warrants and common warrants. A 1‑for‑20 reverse stock split became effective in March 2026, and shares outstanding were 12,810,377 as of March 27, 2026.
Reviva Pharmaceuticals Holdings, Inc. Schedule 13G reports that CVI Investments, Inc. and Heights Capital Management, Inc. together beneficially hold 666,667 shares of common stock, representing 5.2% of the class. The filing states there were 12,727,044 Shares outstanding as of the completion of the offering per the Prospectus Supplement dated March 19, 2026. Heights Capital Management, Inc. is disclosed as investment manager to CVI Investments, Inc. and "may exercise voting and dispositive power" over the shares; the Reporting Persons disclaim beneficial ownership except for their pecuniary interest. The filing is signed by Sarah Travis on March 25, 2026.
Reviva Pharmaceuticals Holdings, Inc. investor Parag Saxena filed an amended Schedule 13D reporting beneficial ownership of 363,280 shares of common stock, or about 2.8% of the 12,810,377 shares outstanding as of March 20, 2026. His holdings include directly owned shares, interests held through various Vedanta-related entities, shares underlying warrants and pre-funded warrants, and fully vested options exercisable within 60 days of the filing date. The filing states that Saxena ceased to be a beneficial owner of more than five percent of Reviva’s common stock on March 20, 2026, and that he has not effected any transactions in the issuer’s securities during the 60 days preceding this amendment.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Chief Financial Officer Prabhu Narayan received a grant of stock options covering 40,925 shares of common stock on the grant date of March 18, 2026. These options have an exercise price of $1.87 per share and expire on March 17, 2036.
The award vests over time under the company’s 2020 Equity Incentive Plan. Of the total, 12,789 option shares vested immediately on the grant date, while the remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028, encouraging long-term alignment with the company.
REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.
One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.
Reviva Pharmaceuticals Holdings, Inc. has entered into agreements for a registered public offering raising aggregate gross proceeds of $10.0 million. The company will sell 6,283,334 shares of common stock and pre-funded warrants for up to 383,333 shares, together with Series G and Series H warrants exercisable for up to 6,666,667 shares each at an exercise price of $1.50 per share. Net proceeds are expected to be approximately $9.0 million, which Reviva plans to use, along with existing cash, to fund research and development, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and general corporate purposes. The warrants are immediately exercisable, with Series G expiring in five years and Series H in one year, and include beneficial ownership limits of 4.99% or 9.99%.
Reviva Pharmaceuticals Holdings, Inc. is offering 6,283,334 shares of common stock together with Series G and Series H common warrants and up to 383,333 Pre-Funded Warrants in a primary, best-efforts offering described in this prospectus supplement.
The combined public offering price is $1.50 per share and accompanying Series G and H Common Warrants; Series G warrants expire five years and Series H warrants expire 12 months after issuance. Pre-Funded Warrants carry a $0.0001 exercise price and may be used to avoid exceeding 4.99% (or, at purchaser election, 9.99%) beneficial ownership limits. The offering may terminate on April 13, 2026 and is expected to settle in a single closing; proceeds to the issuer are described as net of Placement Agent fees.
The prospectus supplement gives effect to a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding used to calculate post-offering figures are 6,443,710 as of March 17, 2026.
Reviva Pharmaceuticals Holdings, Inc. is offering shares of common stock together with Series G and Series H common warrants and pre-funded warrants in a public offering described in this preliminary prospectus supplement, subject to completion.
The offering is structured as bundled common stock (or pre-funded warrants) sold together with one Series G Common Warrant and one Series H Common Warrant per unit, with Series G exercisable for five years and Series H exercisable for 12 months. The company effected a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding were 6,443,710 as of March 16, 2026 (post-split). The offering is a best-efforts, no-minimum offering to be conducted at a fixed public offering price and expected to settle in a single closing. Use of proceeds is stated as funding R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and for working capital and general corporate purposes.